Amgen's Imdelltra Plus Imfinzi Delivers Landmark Overall Survival Win in First-Line Extensive-Stage SCLC

Amgen (NASDAQ: AMGN) said its DLL3-targeted T-cell engager Imdelltra (tarlatamab-dlle), combined with AstraZeneca’s Imfinzi (durvalumab), met the primary overall survival (OS) endpoint in the Phase 3 DeLLphi-305 trial as first-line maintenance for extensive-stage small cell lung cancer (ES-SCLC). The combination also hit its progression-free survival (PFS) and objective response rate (ORR) secondary endpoints. Amgen shares closed at $391.27 on September 9.

The result, announced September 8, makes Imdelltra the first bispecific T-cell engager (BiTE) to show an OS benefit in the first-line maintenance setting for ES-SCLC. The open-label trial randomized 563 patients whose disease had not progressed after initial treatment with durvalumab, platinum-based chemotherapy and etoposide to receive Imdelltra plus durvalumab or durvalumab alone.

Amgen did not disclose a hazard ratio or median OS figure, describing the benefit as statistically significant and clinically meaningful at a pre-specified interim analysis. Detailed data will be presented at an upcoming medical congress and shared with regulators. The company said the safety profile was consistent with the known profiles of both drugs, with no new or unexpected safety signals. Imdelltra carries boxed warnings for cytokine release syndrome (CRS) and neurologic toxicity including ICANS, and the trial required healthcare-setting monitoring for one to two hours after the first two infusions.

The readout positions Amgen to move Imdelltra earlier in the SCLC treatment path. The drug is already the standard in second-line ES-SCLC after its 2024 accelerated approval, converted to full approval in 2025 on the strength of the DeLLphi-304 OS win. SCLC remains aggressive: median survival from first-line maintenance is roughly one year and only about 40% of patients reach second-line therapy.

Competition in first-line maintenance is building. Jazz Pharmaceuticals’ Zepzelca (lurbinectedin) plus Roche’s Tecentriq won FDA approval in 2025 after the IMforte trial showed a 13.2-month median OS versus 10.6 months. Earlier DeLLphi-303 Phase 1b data pointed to a 25.3-month median OS for Imdelltra plus a PD-L1 inhibitor, but the Phase 3 hazard ratio will be the decisive number once full results land.

The stock’s announcement-day move was clouded by unrelated news: Amgen fell about 10% on September 8, a decline Wall Street tied to a Novartis cardiovascular trial setback that raised read-through concerns for Amgen’s own cholesterol franchise rather than the Imdelltra readout. Investors will watch the full DeLLphi-305 dataset, and the still-unreported hazard ratio, to gauge how much of the first-line maintenance market Imdelltra can claim.

What It Means for the Trade

The first thing to do is unstack the two news items. The 10% drop was about cardiovascular read-through, not oncology — which means the market has not yet properly priced a positive DeLLphi-305 into AMGN. When full data with a hazard ratio lands at a congress, the readout gets a second, cleaner trading session. The key numbers to watch: the OS hazard ratio against durvalumab monotherapy, and whether the PFS benefit is large enough to change the maintenance paradigm rather than supplement it. DeLLphi-303’s Phase 1b pointed toward a 25.3-month median OS for the Imdelltra plus PD-L1 combination — cross-trial, not head-to-head with DeLLphi-305’s control arm, but it sets the bar the Phase 3 must approach for the result to be called landmark rather than merely positive.

The commercial geometry is favorable. Imdelltra already owns second-line ES-SCLC after converting its accelerated approval to full on DeLLphi-304’s OS win, and only about 40% of patients ever reach second-line therapy. That 40% funnel is the whole argument for moving the drug into maintenance: every patient treated at maintenance is a patient captured one line earlier, in a setting where the entire duration of benefit accrues to Imdelltra rather than to whatever the patient’s next therapy would have been. First-line maintenance in ES-SCLC is also where Imfinzi’s existing CASPIAN-derived franchise lives, so the combination lets Amgen ride an established maintenance infrastructure — the durvalumab maintenance population already exists; Imdelltra would be added to it, not built alongside it.

Mechanism and Trial Context

The design of DeLLphi-305 is the detail that makes the readout durable. Randomizing 563 patients who had not progressed after chemo-immunotherapy induction to Imdelltra plus durvalumab versus durvalumab alone isolates the marginal contribution of the BiTE on top of the standard maintenance backbone. That is the same logic that built Amgen’s second-line label, and it means the OS benefit, once quantified, will be directly interpretable as “add Imdelltra to what you already do” — the lowest-friction adoption argument in oncology. The open-label design is a caveat worth keeping in view: open-label OS endpoints can pick up care-intensity effects, so the PFS and ORR numbers serve as the confirmatory internal check.

Mechanistically, DLL3 is the reason this works in SCLC at all: it is expressed on tumor cells across most SCLC while staying mostly quiet in normal tissue, which is what lets a T-cell engager redirect cytotoxic T cells onto the tumor without the systemic mayhem of a broadly targeted construct. The BiTE format has known costs — CRS and ICANS boxed warnings, and the one-to-two-hour post-infusion monitoring for the first two doses — but in a maintenance setting where patients are already coming in for durvalumab infusions, the incremental logistics burden is smaller than it was in the heavily pretreated second-line population. The safety profile being “consistent with known profiles” is the quiet win here: no new signal in a maintenance population is exactly what an approvable maintenance label needs.

Risks and What Could Go Wrong

1. The hazard ratio disappoints: “statistically significant and clinically meaningful” without a disclosed number leaves room for a benefit too small to justify maintenance-slot adoption against Jazz/Roche’s lurbinectedin-Tecentriq option.
2. The congress data reveal a subgroup problem — maintenance trials live and die on whether the benefit holds in patients with residual disease burden, and a benefit concentrated in favorable-risk patients will not change practice.
3. Regulatory timing: Amgen said it will share with regulators, but first-line maintenance filings in SCLC will need mature data; an interim-analysis-only filing invites an extended review.
4. The cardiovascular overhang is the actual near-term AMGN driver — the Novartis setback read-through could keep dominating the tape and bury a good oncology story under a bad cardiology narrative.

The position read: the September 8 selloff was mispriced relative to this readout, and the congress presentation is the next catalyst where the market can get the pricing right. The binary is the hazard ratio — wait for it rather than front-running it.

Read our bispecific antibody overview and our coverage of Jazz’s Zepzelca second-line withdrawal.

Source: Amgen press release